Search

Multi-color fluorescent nanodiamonds (FNDs) containing a variety of color centers are promising fluorescent markers for biomedical applications. Compared to colloidal quantum dots and organic dyes, FNDs have the advantage of lower toxicity, exceptional chemical stability, and better photostability. They can be surface functionalized by techniques similar to those used for other nanoparticles. They exhibit a variety of emission wavelengths from visible to near infrared, with narrow or broad bandwidths depending on their color centers. In addition, some color centers can detect changes in magnetic fields, electric fields, and temperature. In this article review, we will discuss the current trends in FND’s development, including comparison to the early development of quantum dots. We will also highlight some of the latest advances in fabrication, as well as demonstrations of their use in bioimaging and biosensing.

Fluorescent nanodiamonds (FNDs) are carbon-based nanomaterials that emit bright, photostable fluorescence and exhibit a modifiable surface chemistry. Myeloid-derived suppressor cells (MDSCs) are an immunosuppressive cell population known to expand in cancer patients and contribute to worse patient outcomes. To target MDSC, glycidol-coated FND were conjugated with antibodies against the murine MDSC markers, CD11b and GR1 (dual-Ab FND). In vitro, dual-Ab FND uptake by murine MDSC was significantly higher than IgG-coated FND (94.7% vs. 69.0%, p < 0.05). In vivo, intra-tumorally injected dual-Ab FND primarily localized to the tumor 2 and 24 h post-injection, as measured by in vivo fluorescence imaging and flow cytometry analysis of the spleen and tumor. Dual-Ab FND were preferentially taken up by intra-tumoral MDSC, representing 87.1% and 83.0% of FND+ cells in the tumor 2 and 24 h post-injection, respectively. Treatment of mice with anti-PD-L1 immunotherapy prior to intra-tumoral injection of dual-Ab FND did not significantly alter the uptake of FND by MDSC. These results demonstrate the ability of our novel dual-antibody conjugated FND to target MDSC and reveal a potential strategy for targeted delivery to other specific immune cell populations in future cancer research.